medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2020, Número 4

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (4)


Coagulación intravascular diseminada y sepsis: tratamiento y criterios diagnósticos

Martínez SLM, Mercado AG

Idioma: Español
Referencias bibliográficas: 52
Paginas: 1-17
Archivo PDF: 379.70 Kb.


RESUMEN

Introducción: La sepsis es un proceso patológico que se caracteriza por un estado inflamatorio desmesurado que puede generar coagulopatías graves como la coagulación intravascular diseminada. Esta coagulopatía se caracteriza principalmente por la exposición del factor tisular que activa la cascada de coagulación y genera un estado protrombótico que puede empeorar la falla orgánica.
Objetivo: Analizar criterios diagnósticos e implicación terapéutica con el fin de mostrar una actualización en el abordaje de un paciente con coagulación intravascular diseminada y sepsis.
Métodos: Se realizó una búsqueda de artículos en la base de datos PubMed, Science direct y Scielo, utilizando los siguientes descriptores: coagulopatía, sepsis, coagulación intravascular diseminada, criterios diagnósticos y tratamiento.
Conclusión: Se ha encontrado una mejora en la mortalidad de los pacientes tratados con anticoagulantes como la proteína C, la antitrombina, entre otros, sin embargo, estos hallazgos no han logrado la trascendencia necesaria para ser recomendados en las guías de tratamiento de coagulación intravascular diseminada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. van der Poll T, Wiersinga WJ. Sepsis, sepsis grave y shock séptico. In: Bennett JE, Dolin R, Blaser MJ. Mandell Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9. ed. New Jersey: Elsevier; 2020.

  2. Fort G, Ferri F. Sepsis. In: Ferri F. Ferri's Clinical Advisor. Philadelphia: Elsevier; 2020.

  3. Organización Panamericana de Salud. Sepsis: General Information. [Internet]. Washington: Organización Panamericana de la Salud; 2018 [acceso 19/06/2020]. Disponible en: Disponible en: https://www.paho.org/hq/index.php?option=com_content&view=article&id=14278:sepsis-general-information&Itemid=72260&lang=es

  4. Rodríguez F, Barrera L, De La Rosa G, Dennis R, Dueñas C, Granados M, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals. Crit Care Med. 2011;39(7):1675-82. DOI: https://10.1097/CCM.0b013e318218a35e.

  5. Morales J. Disseminated Intravascular Coagulation. In: Kellerman R, Rakel D. Conn's current therapy. Philadelphia: Elsevier; 2019.

  6. Boral BM, Williams DJ, Boral LI. Disseminated Intravascular Coagulation. Am J Clin Pathol. 2016;146(6):670-80. DOI: https://10.1093/ajcp/aqw195.

  7. Squizzato A, Hunt BJ, Kinasewitz GT, Wada H, Ten Cate H, Thachil J, et al. Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost. 2016;115(5):896-904. DOI: https://10.1160/TH15-09-0740.

  8. Martin G, Mannino D, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003; 348: 1546-54. DOI: https://10.1056/NEJMoa022139.

  9. Arango M. Coagulación intravascular diseminada. Iatreia. 2010;23(4):344-53.

  10. Jaimes F, Valencia M, Vélez L. Significado clínico de los hemocultivos. Una cohorte retrospectiva en el Hospital San Vicente de Paúl. Infectio. 1998; 2(2):69- 76.

  11. Walborn A, Rondina M, Mosier M, Fareed J, Hoppensteadt D. Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2019;25:1076029619852163. DOI: https://10.1177/1076029619852163

  12. Gruda MC, Ruggeberg KG, O'Sullivan P, Guliashvili T, Scheirer AR, Golobish TD, et al. Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb(r) sorbent porous polymer beads. PLoS One. 2018;13(1):e0191676. DOI: https://10.1371/journal.pone0191676

  13. Keshari R, Silasi R, Popescu N, Georgescu C, Chaaban H, Lupu C, et al. Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. J Thromb Haemost. 2019;18(1):180-90. DOI: http://10.1111/jth.14642

  14. Yamakawa K, Gando S, Ogura H, Umemura Y, Kabata D, Shintani A, et al. Identifying Sepsis Populations Benefitting from Anticoagulant Therapy: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model. Thromb Haemost. 2019;119(11):1740-51. DOI: https://10.1055/s-0039-1693740

  15. Ha SO, Park SH, Hong SB, Jang S. Performance Evaluation of Five Different Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Predicting Mortality in Patients with Complicated Sepsis. J Korean Med Sci. 2016;31(11):1838-45. DOI: https://10.3346/jkms.2016.31.11.1838

  16. Iba T, Levi M, Levy JH. Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. Semin Thromb Hemost. 2020; 46(1):89-95 DOI: https://10.1055/s-0039-1694995

  17. Yamakawa K, Yoshimura J, Ito T, Hayakawa M, Hamasaki T, Fujimi S. External Validation of the Two Newly Proposed Criteria for Assessing Coagulopathy in Sepsis. Thromb Haemost. 2019;119(2):203-12. DOI: https://10.1055/s-0038-1676610

  18. Lyons PG, Micek ST, Hampton N, Kollef MH. Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality. Crit Care Med. 2018;46(5):736-42. DOI: https://10.1097/CCM.0000000000002997

  19. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017;7(9):e017046. DOI: https://10.1136/bmjopen-2017-017046

  20. Iba T, Arakawa M, Di Nisio M, Gando S, Anan H, Sato K, et al. Newly proposed sepsis induced coagulopathy precedes International Society on Thrombosis and Haemostasis overt-disseminated intravascular coagulation and predicts high mortality. J Intensive Care Med. 2020;35(7):643-49. DOI: https://10.1177/0885066618773679

  21. Lyons PG, Micek ST, Hampton N, Kollef MH. Sepsis-Associated Coagulopathy Severity Predicts Hospital Mortality. Crit Care Med. 2018;46(5):736-42. DOI: https://10.1097/CCM.0000000000002997

  22. Yamakawa K, Yoshimura J, Ito T, Hayakawa M, Hamasaki T, Fujimi S. External Validation of the Two Newly Proposed Criteria for Assessing Coagulopathy in Sepsis. Thromb Haemost. 2019;119(2):203-12. DOI: https://10.1055/s-0038-1676610

  23. Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-94. DOI: https://10.1111/jth.14578

  24. Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019; 6(3):223-32. DOI: https://10.1002/ams2.411

  25. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med. 2006;34(3):625-31. DOI: https://10.1097/01.ccm.0000202209.42491.38

  26. Wada H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017; 15:17. DOI: https://10.1186/s12959-017-0142-4

  27. Matsubara T, Yamakawa K, Umemura Y, Gando S, Ogura H, Shiraishi A, et al. Significance of plasma fibrinogen level and antithrombin activity in sepsis: A multicenter cohort study using a cubic spline model. Thromb Res. 2019; 181:17-23. DOI: https://10.1016/j.thromres.2019.07.002

  28. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637. DOI: https://10.1097/CCM.0b013e31827e83af

  29. Delabranche X, Quenot JP, Lavigne T, Mercier E, François B, Severac F, et al. Early Detection of Disseminated Intravascular Coagulation During Septic Shock. Crit Care Med. 2016;44(10):e930-9. DOI: https://10.1097/CCM.0000000000001836

  30. Yamakawa K, Umemura Y, Murao S, Hayakawa M, Fujimi S. Optimal Timing and Early Intervention With Anticoagulant Therapy for Sepsis-Induced Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2019;25. DOI: https://10.1177/1076029619835055

  31. Umemura Y, Yamakawa K. Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan. J Thromb Haemost. 2018;16(3):462-464. DOI: https://10.1111/jth.13946

  32. Yamakawa K, Gando S, Ogura H, Umemura Y, Kabata D, Shintani A, et al. Identifying Sepsis Populations Benefitting from Anticoagulant Therapy: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model. Thromb Haemost. 2019; 119(11):1740-51. DOI: https://10.1055/s-0039-1693740

  33. Levi M, de Jonge E, van der Poll T, ten Cate H. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Semin Thromb Hemost. 2001;27(6):569-75. DOI: https://10.1055/s-2001-18862

  34. Fan Y, Jiang M, Gong D, Zou C. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Sci Rep. 2016;6:25984. DOI: https://10.1038/srep25984

  35. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4(1):90-7 DOI: https://10.1111/j.1538-7836.2005.01697.x

  36. Wiedermann CJ, Hoffman JN, Juers M, Ostermann H, Kienast J, Briegel J, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med. 2006;34(2):285-92. DOI: https://10.1097/01.ccm.0000194731.08896.99

  37. Hoffmann JN, Wiedermann CJ, Juers M, Ostermann H, Kienast J, Briegel J, et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost. 2006;95(5):850-6.

  38. Sawamura A, Gando S, Hayakawa M, Hoshino H, Kubota N, Sugano M. Effects of antithrombin III in patients with disseminated intravascular coagulation diagnosed by newly developed diagnostic criteria for critical illness. Clin Appl Thromb Hemost. 2009;15(5):561-6. DOI: https://10.1177/1076029608323497

  39. Gando S, Saitoh D, Ishikura H, Ueyama M, Otomo Y, Oda S, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17(6):R297 DOI: https://10.1186/cc13163

  40. Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13(4):508-19. DOI: https://10.1111/jth.12841

  41. Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, et al. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. 2019;321(20):1993-2002. DOI: https://10.1001/jama.2019.5358

  42. Yamakawa K, Murao S, Aihara M. Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis. Thromb Haemost. 2019;119(1):56-65. DOI: https://10.1055/s-0038-1676345

  43. Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, et al. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study. Thromb Haemost. 2016;115(6):1157-66. DOI: https://10.1160/TH15-12-0987

  44. Hayakawa M, Kudo D, Saito S, Uchino S, Yamakawa K, Iizuka Y, et al. Antithrombin Supplementation and Mortality in Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. Shock. 2016; 46(6):623-31. DOI: https://10.1097/SHK.0000000000000727

  45. Umemura Y, Yamakawa K, Hayakawa M, Kudo D, Fujimi S. Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study. Clin Appl Thromb Hemost. 2018;24(5):734-40. DOI: https://10.1177/1076029618755948

  46. Ranieri M, Thompson T, Barie PS, Dhainaut JF, Douglas IS, Finfer S, et al. Drotrecogin Alfa (Activated) in Adults with Septic Shock. N Engl J Med. 2012; 366(22):2055-64. DOI: https://10.1056/NEJMoa1202290

  47. Annane D, Timsit JF, Megarbane B, Martin C, Misset B, Mourvillier B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med. 2013;187(10):1091-7. DOI: https://10.1164/rccm.201211-2020OC

  48. Lowes R. Sepsis Drug Xigris Pulled from Worldwide Market - Medscape [Internet]- Oct 25, 2011. DOI: https://www.medscape.com/viewarticle/752169

  49. Iba T, Umemura Y, Watanabe E, Wada T, Hayashida K, Kushimoto S, et al. Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy. Acute Med Surg. 2019;6(3):223-32. DOI: https://10.1002/ams2.411

  50. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006;208(3):327-39. DOI: https://10.1002/path.1871

  51. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238-47. DOI: https://10.1001/jama.290.2.238

  52. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am 52. J Respir Crit Care Med. 2011;183(11):1561-8. DOI: https://10.1164/rccm.201007-1167OC




2020     |     www.medigraphic.com